219 related articles for article (PubMed ID: 30299325)
21. From cachexia to obesity: the role of host metabolism in cancer immunotherapy.
Brocco D; Di Marino P; Grassadonia A
Curr Opin Support Palliat Care; 2019 Dec; 13(4):305-310. PubMed ID: 31389842
[TBL] [Abstract][Full Text] [Related]
22. Cancer cachexia and treatment toxicity.
Chowdhry SM; Chowdhry VK
Curr Opin Support Palliat Care; 2019 Dec; 13(4):292-297. PubMed ID: 31389845
[TBL] [Abstract][Full Text] [Related]
23. Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.
Dunne RF; Mustian KM; Garcia JM; Dale W; Hayward R; Roussel B; Buschmann MM; Caan BJ; Cole CL; Fleming FJ; Chakkalakal JV; Linehan DC; Hezel AF; Mohile SG
Curr Opin Support Palliat Care; 2017 Dec; 11(4):278-286. PubMed ID: 28957880
[TBL] [Abstract][Full Text] [Related]
24. Definition and classification of cancer cachexia: an international consensus.
Fearon K; Strasser F; Anker SD; Bosaeus I; Bruera E; Fainsinger RL; Jatoi A; Loprinzi C; MacDonald N; Mantovani G; Davis M; Muscaritoli M; Ottery F; Radbruch L; Ravasco P; Walsh D; Wilcock A; Kaasa S; Baracos VE
Lancet Oncol; 2011 May; 12(5):489-95. PubMed ID: 21296615
[TBL] [Abstract][Full Text] [Related]
25. Cancer Cachexia: Beyond Weight Loss.
Bruggeman AR; Kamal AH; LeBlanc TW; Ma JD; Baracos VE; Roeland EJ
J Oncol Pract; 2016 Nov; 12(11):1163-1171. PubMed ID: 27858548
[TBL] [Abstract][Full Text] [Related]
26. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
27. [Recent development in research and management of cancer anorexia-cachexia syndrome].
Inui A
Gan To Kagaku Ryoho; 2005 Jun; 32(6):743-9. PubMed ID: 15984510
[TBL] [Abstract][Full Text] [Related]
28. The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise.
Al-Majid S; Waters H
Biol Res Nurs; 2008 Jul; 10(1):7-20. PubMed ID: 18705151
[TBL] [Abstract][Full Text] [Related]
29. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
30. Practical approaches to managing cancer patients with weight loss.
Del Fabbro E; Orr TA; Stella SM
Curr Opin Support Palliat Care; 2017 Dec; 11(4):272-277. PubMed ID: 28957881
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
Currow DC; Skipworth RJ
Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiology of cancer cachexia: much more than host-tumour interaction?
Skipworth RJ; Stewart GD; Dejong CH; Preston T; Fearon KC
Clin Nutr; 2007 Dec; 26(6):667-76. PubMed ID: 17507116
[TBL] [Abstract][Full Text] [Related]
33. FIT: Functional and imaging testing for patients with metastatic cancer.
Roeland EJ; Phull H; Hagmann C; Sera C; Dullea AD; El-Jawahri A; Nelson S; Gallivan A; Ma JD; Nipp RD; Baracos VE
Support Care Cancer; 2021 May; 29(5):2771-2775. PubMed ID: 32990784
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Cancer-Associated Cachexia - How to Approach Physical Function Evaluation.
Fram J; Vail C; Roy I
Curr Oncol Rep; 2022 Jun; 24(6):751-761. PubMed ID: 35305209
[TBL] [Abstract][Full Text] [Related]
35. Skeletal muscle function during the progression of cancer cachexia in the male Apc
VanderVeen BN; Hardee JP; Fix DK; Carson JA
J Appl Physiol (1985); 2018 Mar; 124(3):684-695. PubMed ID: 29122966
[TBL] [Abstract][Full Text] [Related]
36. Cancer cachexia.
Barber MD; Ross JA; Fearon KC
Surg Oncol; 1999 Nov; 8(3):133-41. PubMed ID: 11113664
[TBL] [Abstract][Full Text] [Related]
37. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score.
Douglas E; McMillan DC
Cancer Treat Rev; 2014 Jul; 40(6):685-91. PubMed ID: 24321611
[TBL] [Abstract][Full Text] [Related]
38. Update on anorexia and cachexia.
Strasser F; Bruera ED
Hematol Oncol Clin North Am; 2002 Jun; 16(3):589-617. PubMed ID: 12170570
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of computerized tomography in assessing cancer cachexia.
Prado CM; Birdsell LA; Baracos VE
Curr Opin Support Palliat Care; 2009 Dec; 3(4):269-75. PubMed ID: 19667996
[TBL] [Abstract][Full Text] [Related]
40. Cancer Cachexia: More Than Skeletal Muscle Wasting.
Schmidt SF; Rohm M; Herzig S; Berriel Diaz M
Trends Cancer; 2018 Dec; 4(12):849-860. PubMed ID: 30470306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
